Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 6/20 | 0.40 |
| ▸ | IGF1R | P08069 | 6/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 2/20 | 0.39 |
| ▸ | CCND3 | P30281 | 2/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701629 | 1.00 | INSR (0.40) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL22942147 | 0.88 | MEN1 (0.42) | IGF1RALKEGFR | |
| SCHEMBL29876924 | 0.88 | MEN1 (0.42) | IGF1RALKEGFR | |
| SCHEMBL13832188 | 0.85 | CCNA2 (0.47) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL24940079 | 0.82 | ALK (0.44) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL30487108 | 0.82 | ALK (0.44) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL22028008 | 0.81 | INSR (0.41) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL22026163 | 0.80 | EGFR (0.51) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL30702793 | 0.80 | EGFR (0.51) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL22025893 | 0.80 | EGFR (0.52) | INSRIGF1RALKCDK9CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116888108-B | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116888108-A | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-115677772-B | Compound and composition for EGFR kinase inhibitor and application thereof | 浙江大学智能创新药物研究院 | 2023-08-18 | — | — | CN | disclosed |
| CN-116082399-A | Condensed ring-2-aminopyrimidine compound, and composition and application thereof | 浙江大学智能创新药物研究院 | 2023-05-09 | — | — | CN | disclosed |
| CN-115677772-A | Compound and composition for EGFR kinase inhibitor and application of compound and composition | 浙江大学智能创新药物研究院 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023006088-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION AND USE THEREOF | 浙江大学智能创新药物研究院 | 2023-02-02 | — | — | WO | disclosed |
| WO-2022268229-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | 和径医药科技（上海）有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2021018003-A1 | EGFR INHIBITOR, COMPOSITION, AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-02-04 | — | — | WO | disclosed |
| WO-2021018009-A1 | EGFR INHIBITOR, COMPOSITION, AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-02-04 | — | — | WO | disclosed |